Глава 10. Применение стабилизаторов настроения 465

liminary study. Arch Gen Psychiatry 1990; 47: 435-440.

47. Ballinger JC. The use of anticonvulsants in ma­nic-depressive illness. J Clin Psychiatry 1988; 49 (Supplll):21-25.

48. Post RM. Introduction: emerging perspectives on valproate in affective disorders. J Clin Psychiatry 1989; 50 (Suppl 3): 3-9.

49. Post RM, Berrettini W, Uhde TW. Selective res­ponse to the anticonvulsant carbamazepine in manic-depressive illness: a case study. J Clin Psy-chopharmacol 1984; 4:178-185.

50. Lambert PA, Cavaz G, Borselli S, Carrel S. Action neuro-psychotrope d'un novel antiepeliptique: le depainide. Ann Med Psychol 1966; 1: 707-710.

51. Pope HG Jr, McElroy SL, Keck PE, Hudson JL. A placebo-controlled study of valproate in mania. Arch Gen Psychiatry 1991; 48:62-68.

52. Brennan MJW, Sandyk R, Borsook D. Use of so­dium valproate in the management of affective disorders: basic and clinical aspects. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984: 56-65.

53. Emrich HM, Dose M, Zerssen DV. The use of so­dium valproate, carbamazepine, and oxcarbaze-pine in patients with affective disorders. J Affec­tive Disord 1985; 8: 243-250.

54. McElroy SL, Keck PE, Pope HG, et al. Correlates of antimanic response to valproate. Psychophar-macol Bull 1991; 27:127-133.

55. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treat­ment of mania. JAMA 1994; 271 (12): 918-924.

56. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Predictors of valproate response in bipolar

rapid cycling. J Clin Psychopharmacol 1993; 13 (4): 280-283.

57. Papatheodorou G, Kutcher SP. Divalproex sodi­um treatment in late adolescent and young adult acute mania. Psychopharmacol Bull 1993; 29 (2): 213-219.

58. Papatheodorou G, Kutcher SP, Katie M, Szalai JP. The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J Clin Psy­chopharmacol 1995; 15:110-116.

59. Risinger RC, Risby ED, Risch SC. Saftey and ef­ficacy of divalproex sodium in elderly bipolar patients [Letter]. J Clin Psychiatry 1994; 55 (5): 215.

60. Stall AL, Banov M, Kollerener M, et al. Neurolo­gic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14: 311-313.

61. Freeman TW, Clothier JL, Pazzaglia P, Lesem MC, Swann AC. A double-blind comparison of val­proate and lithium in the treatment of acute ma­nia. Am J Psychiatry 1992; 149:108-111.

62. Bowden CL, Janicak PG, Orsulak P, et al. Relation­ship of serum valporate concentration to respon­se in mania. Am J Psychiatry 1996; 153:765-770.

63. Keck PE, McElroy SL, Tugrul KG, Bennet JA. Val­proate oral loading in the treatment of acute ma­nia. J Clin Psychiatry 1993; 54: 305-308.

64. Wassef A, Watson DJ, Morrison P, Bryant S, Flack J. Neuroleptic-valproic acid combination in treat­ment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989; 9 (1): 45-48.

65. McFarland BH, Miller MR, Straumfjord AA. Val­proate use in the older manic patient. J Clin Psy­chiatry 1990; 51 (11): 479-481.

У подавляющего большинства больных, перенесших маниакальное состояние, в последующем обязательно возникнут по­вторные приступы. Эти приступы часто но­сят асоциальный характер, могут представлять реальную угрозу для жизни больного и ведут к

нарастающему ухудшению способности выпол­нять повседневные социальные функции. По­этому очень важно иметь возможность для про­ведения эффективной и безопасной терапии продолжительное время. Идеально было бы иметь лекарственное средство, которое оказы-